Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients

DOI: 10.5402/2012/436046

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text